IMMUNOTHERAPY

Clinical benefit, including partial response and stable disease, was observed in 11 of 20 patients with relapsed metastatic sarcoma following nivolumab treatment that was administered either alone or in combination with pazopanib.

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, discusses current and emerging immunotherapeutic strategies in the field of melanoma during an interview at the 34th Annual Chemotherapy Foundation Symposium^TM.

Updated results of the multicenter phase II study SARC028 demonstrate both a favorable safety profile as well as encouraging efficacy for the use pembrolizumab (Keytruda) as a treatment for patients with advanced sarcomas.

The PD-1 inhibitor nivolumab extended overall survival versus placebo for patients who were refractory or intolerant to standard therapy with unresectable, advanced, or recurrent gastric cancer, according to topline data from the phase III ONO-4538-12 trial.

Treatment with pembrolizumab, an immunotherapeutic agent approved in melanoma, lung, and head and neck cancer, and which is undergoing investigation in several other cancer types, reduced the size of tumors in patients with a specific soft tissue sarcoma.

The FDA has approved the PD-1 inhibitor nivolumab as a treatment for patients with metastatic or recurrent squamous cell carcinoma of the head and neck following progression on platinum-based therapy.

Immune checkpoint inhibitor development is progressing as treatments for patients with acute myeloid leukemia and myelodysplastic syndrome, with a number of studies currently assessing new combination strategies.

Studies testing immune checkpoint inhibitors in combination with other agents for the treatment of both Hodgkin and non-Hodgkin lymphoma are garnering attention among researchers.

Alessandro Gronchi, MD, president, Connective Tissue Oncology Society (CTOS), discusses some of the exciting data that will be presented at the 21st annual CTOS meeting in Lisbon, Portugal.

The key to inducing durable responses with immunotherapy in multiple myeloma may depend on the effective use of combination strategies, particularly for the use of monoclonal antibodies.

David F. McDermott, MD, discusses methods of expanding on progress seen in the field of immunotherapy, both in the case of kidney cancer and other tumor types at the PER® European Congress on Immunotherapies in Cancer held in Barcelona.

An overview of the data and rationale that led to the approval of nivolumab and pembrolizumab for NSCLC, with an emphasis on specific patient populations likely to benefit from this approach and future directions for clinical research in this area.

In an interview, Yvonne Saenger, MD, discussed ongoing developments with immunotherapy in melanoma.

The Society for Immunotherapy of Cancer’s (SITC) Annual Meeting & Associated Programs are renowned as a catalyst for future advances in the cancer immunotherapy field. This year marks the 31st such conference (SITC 2016), which will be held in National Harbor, Maryland from November 9 to 13, 2016.

James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.

For the first time, Physicians’ Education Resource (PER®) will host 2 European conferences, providing more opportunities for oncology professionals worldwide to learn and collaborate with leading experts in the fields.

Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.

Dmitriy Zamarin, MD, PhD, details 5 categories of immunotherapy strategies currently undergoing development.

Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with lung cancer have shown promising results for these combinations. 

As new drugs and combinations gain approvals for a broad range of malignancies, there is a growing need for disease-specific recommendations to help guide the integration of immunotherapy treatments into current practice. 

In an interview with <em>Targeted Oncology</em>, Naiyer Rizvi, MD, director of Thoracic Oncology and Immunotherapy at Columbia University Medical Center, discusses data from the&nbsp;phase III KEYNOTE-024 trial and expressed his optimism about immunotherapy in the NSCLC field.

Newer agents, including immunotherapies and HER2 and VEGF-targeted therapies, are being investigated in gastric cancer, but the jury is still out on if these therapies will be beneficial, said David H. Ilson, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center.<br /> &nbsp;

Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.

Hope S. Rugo, MD, discusses&nbsp;immunotherapies, androgen receptor (AR)-targeted agents, and targeted therapies all on the horizon in TNBC.

Goals of &quot;Project Impact: A Campaign to Defeat Pediatric Brain Tumors&quot;&nbsp;include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas.